Cargando…
The role of (68)Gallium-prostate-specific membrane antigen positron emission tomography on staging of high-risk localized prostate cancer: for all high-risk patients or would it be better to select them?
BACKGROUND: According to pathologico-clinical features, patients diagnosed with localized prostate cancer (PCa) are stratified into distinct risk groups (low-risk, intermediate-risk or high-risk). Data have demonstrated that (68)Gallium-prostate-specific membrane antigen positron emission tomography...
Autores principales: | Monteiro, Fernando Sabino M., Eliam, Juçara Motta Serafim, Gomes de Jesus, Rafaela, Cavalcante, Pedro, Gomes, Gustavo do Vale, Hochhegger, Bruno, Gonçalves, Vinicius K., Von Wallwitz Freitas, Laura, Roman, Diego H., Fay, Andre Poisl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053688/ https://www.ncbi.nlm.nih.gov/pubmed/33912515 http://dx.doi.org/10.1016/j.prnil.2020.07.007 |
Ejemplares similares
-
Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer
por: El Hajj, Albert, et al.
Publicado: (2019) -
The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer
por: Kulkarni, Meghana, et al.
Publicado: (2019) -
Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023) -
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018) -
Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)